SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Talis Biomedical Corporation (TLIS) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 29/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — TLIS
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio12.53
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-34.12
Book Value / Share$0.00
Revenue / Share$0.23
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-141.85 |
$2.39M |
$-21.34M |
-892.8% |
| 2019 |
$-182.88 |
$3.98M |
$-27.43M |
-689.8% |
| 2020 |
$-314.06 |
$10.94M |
$-91.08M |
-832.7% |
| 2021 |
$-126.13 |
$0.00 |
$-190.46M |
- |
| 2022 |
$-62.45 |
$3.65M |
$-110.89M |
-3036.3% |
| 2023 |
$-34.12 |
$412K |
$-62.01M |
-15050.2% |
